It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment.<unk>  was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008 for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".<unk>  was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
Panitumumab
Necitumumab
Cetuximab
Sorafenib
Dasatinib
Neratinib
Fostamatinib
Tucatinib